The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Zoledronic Acid Prevents Bone Loss after Liver Transplantation: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
BACKGROUND: Clinically important rapid bone loss occurs within 3 to 6 months after liver transplantation and may be associated with osteoporotic fractures. OBJECTIVE: To determine whether bisphosphonate treatment with zoledronic acid reduces transplant-related bone loss more than placebo in adults having liver transplantation for chronic liver disease. DESIGN: 12-month randomized, double-blind, placebo-controlled trial. SETTING: 2 large liver transplantation centers in Australia. PATIENTS: 62 adults having liver transplantation for chronic liver disease. INTERVENTIONS: Infusions of zoledronic acid, 4 mg (n = 32), or saline (n = 30) were given within 7 days of transplantation and again at months 1, 3, 6, and 9 after transplantation. All patients received supplementation with calcium carbonate, 600 mg/d, and ergocalciferol, 1000 U/d. MEASUREMENTS: The primary outcome was bone mineral density (BMD) measured by dual x-ray absorptiometry before transplantation and 3, 6, and 12 months later. Secondary outcomes included bone turnover markers that were measured before transplantation and 1, 3, 6, 9, and 12 months later. RESULTS: There were statistically significant interactions between treatment effects and time for BMD measurements at the lumbar spine (P = 0.002), femoral neck (P = 0.001), and total hip (P < 0.001). Differences in acute bone loss 3 months after transplantation favored zoledronic acid over placebo. Differences between groups in percentage change from baseline adjusted for baseline weight and serum parathyroid hormone (PTH) level were 4.0% (95% CI, 1.1% to 7.0%) for the lumbar spine, 4.7% (CI, 1.9% to 7.6%) for the femoral neck, and 3.8% (CI, 1.7% to 6.0%) for the total hip. At 12 months after transplantation, the difference in percentage change from baseline between the 2 groups adjusted for baseline weight and serum PTH level was 1.1% (CI, -2.1% to 4.4%) for the lumbar spine, 2.7% (CI, 0.0% to 5.4%) for the femoral neck, and 2.4% (CI, 0.1% to 4.7%) for the total hip. Treatment with zoledronic acid induced temporary secondary hyperparathyroidism and postinfusion hypocalcemia statistically significantly more often than did placebo. LIMITATIONS: The trial was not powered to assess fractures, and 10 of 62 (16%) patients were not included in adjusted analyses because of missing weight or serum PTH measurements. CONCLUSION: Treatment with zoledronic acid can prevent bone loss within the first year after liver transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gallego-Rojo, F. J., Gonzalez-Calvin, J. L., Muñoz-Torres, M., Mundi, J. L., Fernandez-Perez, R., & Rodrigo-Moreno, D. (1998) · Hepatology · doi:10.1002/hep.510280315 · Cited by 241
Monegal, A., Navasa, M., Guañabens, N., Peris, P., Pons, F., Martinez de Osaba, M. J., Ordi, J., Rimola, A., Rodés, J., & Muñoz-Gómez, J. (2001) · Osteoporosis International · doi:10.1007/s001980170094 · Cited by 183
Dodidou, P., Bruckner, T., Hosch, S., Haass, M., Klar, E., Sauer, P., Ziegler, R., & Leidig-Bruckner, G. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1315-x · Cited by 57
Regional bone mineral density after orthotopic liver transplantation
Hussaini, S. H., Oldroyd, B., Stewart, S. P., Roman, F., Smith, M. A., Pollard, S., Lodge, P., OʼGrady, J. G., & Losowsky, M. S. (1999) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199902000-00016 · Cited by 42 · cited 1×
“Although earlier transplantation studies predominantly showed bone loss in the lumbar spine and vertebral fractures (17), several recent reports support our finding of substantial and sustained bone loss in the hip (17, 18, 21, 22).”
Result
Cited by
EASL Clinical Practice Guidelines on nutrition in chronic liver disease
Merli, M., Berzigotti, A., Zelber-Sagi, S., Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., & Parés, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.024 · Cited by 1,130
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Sinclair, M., Grossmann, M., Hoermann, R., Angus, P. W., & Gow, P. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.007 · Cited by 269
Self-citationBone disorders in chronic liver disease
Collier, J. (2007) · Hepatology · doi:10.1002/hep.21852 · Cited by 238
Metadata
- Authors
- Crawford, B. A. L., Kam, C., Pavlovic, J., Byth, K., Handelsman, D. J., Angus, P. W., & McCaughan, G. W.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2006-02-21
- Volume
- 144
- Issue
- 4
- Pages
- 239-248
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2069755592
- Cited by
- 158
- References
- 4
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zoledronic Acid Prevents Bone Loss after Liver Transplantation: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-144-4-200602210-00005
- The paper
- Crawford, B. A. L., Kam, C., Pavlovic, J., Byth, K., Handelsman, D. J., Angus, P. W., & McCaughan, G. W. (2006). Zoledronic Acid Prevents Bone Loss after Liver Transplantation: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-144-4-200602210-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.